• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Nov 1995; 54(11): 886–890.
PMCID: PMC1010038

Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.


OBJECTIVE--To assess the potential of markers of collagen metabolism to reflect disease processes in rheumatoid arthritis (RA). METHODS--Serum (S) and synovial fluid (SF) from 59 patients with RA, and a knee joint effusion and serum from 90 control subjects were studied with radioimmunoassays for the aminoterminal propeptides of type I and type III procollagens (PINP and PIIINP, respectively). The breakdown of type I collagen was quantified with a radioimmunoassay for the cross linked carboxyterminal telopeptide of type I collagen (ICTP). RESULTS--About 50% of the patients had increased S-ICTP and S-PIIINP values, whereas S-PINP was increased in only 20% of the patients. The mean SF:S ratios of these markers varied between 4 (for ICTP) and 340 (for PIIINP), indicating that markers of collagen metabolism are formed locally and then released into the circulation. SF-PINP and SF-PIIINP correlated with each other (rs = 0.86, p < 0.001) and with SF-ICTP (rs = 0.69, p < 0.001, and rs = 0.65, p < 0.001, respectively). SF-ICTP was clearly related to radiographic findings in the corresponding knee joint, patients with gross bone deformation having the greatest SF-ICTP concentrations. S-ICTP and S-PIIINP also correlated with conventional markers of disease activity, such as C reactive protein and joint swelling score. CONCLUSION--Markers of collagen metabolism both in serum and synovial fluid can be measured to provide an assessment of disease process in patients with RA. ICTP and PIIINP are the most informative.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (950K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered? Mayo Clin Proc. 1988 Jan;63(1):58–68. [PubMed]
  • Kushner I. C-reactive protein in rheumatology. Arthritis Rheum. 1991 Aug;34(8):1065–1068. [PubMed]
  • Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum. 1989 Feb;32(2):221–229. [PubMed]
  • Brower AC. Use of the radiograph to measure the course of rheumatoid arthritis. The gold standard versus fool's gold. Arthritis Rheum. 1990 Mar;33(3):316–324. [PubMed]
  • Peel N, Eastell R, Russell G. Markers of bone and collagen breakdown in early inflammatory arthritis. Baillieres Clin Rheumatol. 1992 Jun;6(2):351–372. [PubMed]
  • Poole AR. Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis. 1994 Jan;53(1):3–5. [PMC free article] [PubMed]
  • Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994 Aug;20(3):589–607. [PubMed]
  • Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis. 1993 Dec;52(12):866–869. [PMC free article] [PubMed]
  • Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol. 1994 Nov;33(11):1012–1016. [PubMed]
  • Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed]
  • Hørslev-Petersen K, Bentsen KD, Junker P, Lorenzen I. Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions. Arthritis Rheum. 1986 May;29(5):592–599. [PubMed]
  • Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine. Ann Rheum Dis. 1988 Feb;47(2):116–126. [PMC free article] [PubMed]
  • Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988 Apr;34(4):715–718. [PubMed]
  • Gressner AM, Neu HH. N-terminal procollagen peptide and beta 2-microglobulin in synovial fluids from inflammatory and non-inflammatory joint diseases. Clin Chim Acta. 1984 Aug 31;141(2-3):241–245. [PubMed]
  • Hørslev-Petersen K, Saxne T, Haar D, Thomsen BS, Bentsen KD, Junker P, Lorenzen I. The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis. Rheumatol Int. 1988;8(1):1–9. [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed]
  • Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. [PubMed]
  • Jensen LT, Henriksen JH, Olesen HP, Risteli J, Lorenzen I. Lymphatic clearance of synovial fluid in conscious pigs: the aminoterminal propeptide of type III procollagen. Eur J Clin Invest. 1993 Dec;23(12):778–784. [PubMed]
  • Kotaniemi A, Isomäki H, Hakala M, Risteli L, Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol. 1994 Sep;21(9):1593–1596. [PubMed]
  • Kröger H, Risteli J, Risteli L, Penttilä I, Alhava E. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann Rheum Dis. 1993 May;52(5):338–342. [PMC free article] [PubMed]
  • McDonald JN, Levick JR. Evidence for simultaneous bidirectional fluid flux across synovial lining in knee joints of anaesthetized rabbits. Exp Physiol. 1992 May;77(3):513–515. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...